Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new position in Biohaven Ltd. (NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing.

What happened

According to an SEC filing dated February 17, 2026, Sarissa Capital Management initiated a new stake in Biohaven during the fourth quarter, purchasing 513,184 shares. The quarter-end valuation of the new position stood at $5.79 million, reflecting the total value of shares held after the trade.

What else to know

• This was a new position for Sarissa, bringing Biohaven Ltd. to 2.6% of reportable U.S. equity AUM.
• Top holdings after the filing:
  • NASDAQ:INVA: $56.29 million (25.3% of AUM)
  • NASDAQ:IRWD: $53.65 million (24.1% of AUM)
  • NASDAQ:NBIX: $43.00 million (19.3% of AUM)
  • NASDAQ:CYTK: $25.18 million (11.3% of AUM)
  • NASDAQ:AMRN: $23.35 million (10.5% of AUM)
• As of Monday, Biohaven shares were priced at $8.90, down a staggering 70% over the past year and well underperforming the S&P 500, which is instead up about 15% in the same period.

Company overview

Company snapshot

• Biohaven develops therapies for neurological and immunoscience diseases; currently focused on clinical-stage drug candidates.
• The firm operates a biopharmaceutical business model centered on research and development, with future revenue expected from licensing and commercialization of proprietary treatments.
• It targets healthcare providers and patients affected by neurological and immune-related conditions as primary customers.

Biohaven Ltd. is a clinical-stage biotechnology company specializing in the development of innovative therapies for neurological and immunoscience disorders. With a focus on advancing novel drug candidates, the company leverages proprietary research to address unmet medical needs. Biohaven aims to establish a competitive position through its commitment to scientific innovation and targeted therapeutic development.

What this transaction means for investors

Biohaven today is a reset story. The FDA rejection of troriluzole and a string of disappointing trial updates crushed sentiment, but the underlying strategy hasn’t disappeared. Management is now concentrating resources on a smaller set of late-stage programs, including its degrader platform and a Phase 2 obesity candidate with data expected later this year. That kind of focus matters when capital is tight.

The balance sheet is still holding up better than you might expect for a company in this position. Biohaven ended 2025 with roughly $322 million in cash and raised another $178.9 million after year-end, buying it time to get through key clinical readouts. Meanwhile, its obesity program just completed enrollment, setting up a potential catalyst in the second half of 2026 .

Put this in context of the portfolio, and the logic becomes clearer. This is a fund that already leans heavily into clinical-stage biotech, so adding a distressed name fits the playbook. Upcoming data and execution will matter most next.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.